Autolus Therapeutics (NASDAQ:AUTL) Releases Earnings Results, Beats Expectations By $0.06 EPS

Key Points

• Autolus Therapeutics reported earnings per share of ($0.18), surpassing the expected ($0.24) by $0.06, with revenues reaching $13.50 million for the quarter.
• The company's stock had a trading volume of 3,504,428 shares, surpassing its average volume of 1,776,774, and the stock is currently at $2.17, following a 90.5% increase in Geode Capital's holdings.
• Analysts remain optimistic, with a buy rating from Needham & Company and an average price target for the stock set at $9.32.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.06, Zacks reports. The business had revenue of $13.50 million for the quarter, compared to analyst estimates of $12.92 million.

Autolus Therapeutics Stock Performance

NASDAQ:AUTL traded down $0.31 during trading hours on Tuesday, hitting $2.17. 3,504,428 shares of the company's stock traded hands, compared to its average volume of 1,776,774. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.00. The stock's fifty day moving average price is $2.34 and its two-hundred day moving average price is $1.90. The firm has a market cap of $576.19 million, a P/E ratio of -2.46 and a beta of 1.90.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reissued a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Monday, July 21st. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Autolus Therapeutics has an average rating of "Buy" and an average price target of $9.32.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its holdings in shares of Autolus Therapeutics by 90.5% during the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company's stock valued at $375,000 after purchasing an additional 78,058 shares in the last quarter. Jane Street Group LLC increased its position in Autolus Therapeutics by 809.4% during the first quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock worth $159,000 after buying an additional 91,222 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after buying an additional 11,381 shares during the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.